Can-Fite completes patient enrollment in Phase 2a pancreatic cancer trial.

Can-Fite BioPharma has completed patient enrollment in its Phase 2a pancreatic cancer clinical trial of Namodenoson. The trial is evaluating the safety, clinical activity, and pharmacokinetics of Namodenoson in patients with advanced pancreatic adenocarcinoma who have progressed following at least one line of prior therapy. Top-line efficacy data is expected in Q3 2026.